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Abstract
Background: The aim of this systematic review was to compare clinical, radiographic 
and patient-reported outcomes (PROMs) in intra-bony defects treated with regen-
erative surgery or access flap.
Materials and Methods: A systematic review protocol was written following the 
PRISMA checklist. Electronic and hand searches were performed to identify rand-
omized clinical trials (RCTs) on regenerative treatment of deep intra-bony defects 
(≥3 mm) with a follow-up of at least 12 months. Primary outcome variables were 
probing pocket depth (PPD) reduction, clinical attachment level (CAL) gain and tooth 
loss. Secondary outcome variables were Rec, radiographic bone gain, pocket “clo-
sure,” PROMs and adverse events. Meta-analysis was carried out when possible. 
To evaluate treatment effect, odds ratios were combined for dichotomous data and 
mean differences for continuous data using a random-effect model.
Results: A total of 79 RCTs (88 articles) published from 1990 to 2019 and account-
ing for 3,042 patients and 3,612 intra-bony defects were included in this systematic 
review. Only 10 of included studies were rated at low risk of bias. A total of 13 meta-
analyses were performed. All regenerative procedures provided adjunctive benefit 
in terms of CAL gain (1.34 mm; 0.95–1.73) compared with open flap debridement 
alone. Both enamel matrix derivative (EMD) and guided tissue regeneration (GTR) 
were superior to OFD alone in improving CAL (1.27 mm; 0.79–1.74 mm and 1.43 mm; 
0.76–2.22, respectively), although with moderate–high heterogeneity. Among bioma-
terials, the addition of deproteinized bovine bone mineral (DBBM) improved the clini-
cal outcomes of both GTR with resorbable barriers and EMD. Papillary preservation 
flaps enhanced the clinical outcomes. The strength of evidence was low to moderate.
Conclusion: EMD or GTR in combination with papillary preservation flaps should be 
considered the treatment of choice for residual pockets with deep (≥3 mm) intra-
bony defects.
K E Y W O R D S
enamel matrix derivatives, intra-bony defect, meta-analysis, periodontal pocket, periodontal 
regeneration, systematic review
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1  | BACKGROUND
Periodontal intra-bony defects (also called “vertical” defects) are 
an anatomical sequela of periodontal disease progression, with a 
base apical to the inter-dental alveolar crest, surrounded by one, 
two or three bony walls (Lang, 2000). These defects are associated 
with a higher risk of progression (Papapanou & Wennstrom, 1991) 
and, as such, are often considered to require surgical intervention 
beyond cause-related periodontal therapy. Pioneering studies in 
the 1970s and 1980s have shown that intra-bony defects have po-
tential for healing through regeneration using barrier membranes, 
including the formation of new attachment, re-growth of peri-
odontal ligament and bone measurable clinically, radiographically 
and histologically (Nyman, Lindhe, Karring, & Rylander, 1982). 
Among the various materials employed today, there is currently 
evidence of true periodontal regeneration (periodontal ligament, 
cementum and bone) for decalcified freeze-dried bone allograft 
(DFDBA) (Bowers et al., 1989), demineralized bovine bone min-
eral (DBBM) (Mellonig, 2000) and enamel matrix derivative (EMD) 
(Bosshardt, Sculean, Windisch, Pjetursson, & Lang, 2005). On the 
contrary, bioactive glass (BG) (Nevins et al., 2000), hydroxyapa-
tite (HA) (Stahl & Froum, 1987) and tricalcium phosphate (TCP) 
(Froum & Stahl, 1987), although efficient for improving clinical pa-
rameters, have histologically shown limited evidence of regenera-
tion. Furthermore, the regenerative effect was demonstrated for 
platelet-derived factors (Ridgeway, Mellonig, & Cochran, 2008), 
although no histologic evidence for periodontal regeneration is 
yet available for autogenous platelet-rich plasma (PRP) and plate-
let-rich fibrin (PRF).
A plethora of human clinical studies followed, showing variable 
improvements in clinical and radiographic measurements of peri-
odontal disease after regenerative surgical procedures compared 
with access flaps (Cortellini & Tonetti, 2015; Esposito, Grusovin, 
Papanikolaou, Coulthard, & Worthington, 2009; Needleman, 
Worthington, Giedrys-Leeper, & Tucker, 2006). Several tech-
niques and biomaterials have been employed for periodontal 
regeneration of intra-osseous defects, including minimally in-
vasive techniques with or without regenerative devices, pro-
posed to reduce treatment time, costs and morbidity (Cortellini 
& Tonetti, 2011; Harrel, 1999; Trombelli, Farina, & Franceschetti, 
2007). A recent consensus report of the American Academy of 
Periodontology considers surgical intervention the treatment of 
choice for intra-bony defects (Reynolds et al., 2015). However, 
guidelines for the surgical treatment of intra-bony defects are 
needed, to improve the clarity on indications of different tech-
niques and biomaterials.
The aim of this systematic review was to compare clinical, ra-
diographic and patient-reported outcomes in the treatment of in-
tra-bony defects treated with regenerative surgery or access flap. 
Based on this, guidelines for the regenerative treatment of peri-
odontal intra-bony defects will be proposed.
2  | MATERIAL S AND METHODS
A systematic review protocol was written in the planning stages, and 
the PRISMA statement (Moher, Liberati, Tetzlaff, & Altman, 2009) 
was followed in both the planning and reporting of the review. The 
protocol was registered on 08 February 2019 with PROSPERO 
(available from ID: CRD42019124022).
2.1 | Focused question
The present review aimed to answer two focused questions:
• Does regenerative surgery of intra-bony defects provide addi-
tional clinical benefits measured as probing pocket depth (PPD) 
reduction, clinical attachment level (CAL) gain, recession (Rec) 
and bone gain (BG) in periodontitis patients compared with access 
flap?
Clinical Relevance
Scientific rationale for the study: The aim of this systematic 
review was to assess the clinical efficacy of regenerative 
procedures in the treatment of residual pockets associated 
with intra-bony defects ≥3 mm.
Principal findings: The use of enamel matrix derivative 
(EMD) or resorbable barriers (res-GTR) was associated 
with higher clinical benefit compared with open flap for 
debridement (OFD) alone. No significant difference was re-
ported when comparing EMD and res-GTR. Among bioma-
terials, deproteinized bovine bone mineral (DBBM) seems 
to provide additional clinical benefits to both EMD and res-
GTR. Non-resorbable membranes for GTR were associated 
with higher post-operative morbidity and higher incidence 
of complications, compared with resorbable membranes. 
The use of papillary preservation flap is critical to obtain 
successful outcomes. Initial and heterogeneous data seem 
to support the use of platelet-rich plasma (PRP)/platelet-
rich fibrin (PRF) in addition to OFD, although no defini-
tive proof of histologic regeneration of new attachment is 
available.
Practical implications: Evidence supports the use of EMD 
or res-GTR as the treatment of choice for deep intra-bony 
defects. The addition of DBBM should be considered espe-
cially for the treatment of wider defects. Soft tissue man-
agement according to the principles of papilla preservation 
techniques should be routinely applied to obtain success-
ful outcomes.
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• Is there a difference among regenerative procedures in terms of 
clinical and radiographic gains in intra-bony defects?
2.2 | Eligibility criteria
Criteria used in this systematic review (SR) for studies selection were 
based on the PICOS method and were the following:
• (P) Types of participants: Adult human patients with periodontitis 
who have completed a cycle of non-surgical periodontal therapy 
and present with residual pockets and intra-bony defects (defects 
with a base apical to the inter-dental alveolar crest, surrounded by 
one, two or three bony walls or a combination with at least 3 mm 
of intra-bony component).
• (I) Types of interventions: (A) Any type of regenerative surgery 
with guided tissue regeneration (GTR), enamel matrix derivative 
(EMD), bone filler or substitutes, growth factors (GF) or combi-
nation. (B) Access flap surgery (any type of mucoperiosteal flap 
providing access to the root for debridement followed by re-posi-
tioning of the gingiva at pre-surgical level).
• (C) Comparison between interventions: All possible comparisons 
between access flap surgery and regenerative procedures or be-
tween regenerative procedures.
• (O) Type of outcome measures:
Primary outcomes: CAL gain, PD reduction and tooth loss.
Secondary outcomes: Rec, radiographic bone gain (BG), pocket 
“closure” (namely presence of PD at experimental site ≤4 mm 
at study follow-up), PROMs (patient-reported outcome mea-
sures) and adverse events (AE).
• (S) Types of studies: Only randomized controlled clinical trials 
(RCTs) were considered.
The following additional inclusion criteria were considered:
• RCTs, with or without a split-mouth design comparing the results 
of at least 2 of the investigated surgical techniques above in pa-
tients with periodontal intra-bony defects ≥3 mm;
• including at least 10 patients per arm;
• with at least 12-month follow-up. According to follow-up du-
ration, the studies were divided into short-term observations 
(1–3 years) and long-term observations (>3 years);
• only studies published in English were considered (due to the time 
constraints of this review).
In this SR, the following items were considered as exclusion 
criteria:
• RCTs comparing variations of a same technique (i.e. EMD with or 
without doxycycline).
• RCTs with unclear/not specified type of treated intra-bony 
defects.
• RTCs treating multiple intra-bony defects, furcation defects or 
both single intra-bony defects and furcation defects.
• RTCs with multiple treated sites into a single patient without ap-
propriate statistical analysis and unavailable individual patient 
data (IPD).
2.3 | Information sources and search
An expert reviewer (U.P.) conducted a search on electronic data-
bases until 31 January 2019 to identify studies suitable for this re-
view. Three online evidence sources were used:
1. The National Library of Medicine (MEDLINE by PubMed).
2. The Cochrane Database Trials Register.
3. Scopus.
The search strategies used for each online database are pub-
lished in Appendix S1; Appendix S2; Appendix S3.
Hand searching included a complete search of Journal of Clinical 
Periodontology, Journal of Periodontology, Journal of Periodontal Research 
and Journal of Dental Research from January 2000 to January 2019.
The search was complemented by a screening of the Open Grey 
database and of the reference lists of included studies and previous 
systematic reviews or guidelines dealing with regenerative surgi-
cal procedures for the treatment of periodontal intra-bony defects 
(Cãlin & Pãtraşcu, 2016; Castro et al., 2017; Darby & Morris, 2013; 
Del Fabbro, Bortolin, Taschieri, & Weinstein, 2011; Esposito et al., 
2009; Giannobile & Somerman, 2003; Graziani et al., 2012; Hou, 
Yuan, Aisaiti, Liu, & Zhao, 2016; Kao, Nares, & Reynolds, 2015; 
Khojasteh, Sogeilifar, Mohajerani, & Nowzari, 2013; Khoshkam 
et al., 2015; Koop, Merheb, & Quirynen, 2012; Matarasso et al., 
2015; Miron et al., 2017; Murphy & Gunsolley, 2003; Needleman 
et al., 2006; Pagliaro et al., 2008; Panda, Doraiswamy, Malaiappan, 
Varghese, & Fabbro, 2016; Parrish, Miyamoto, Fong, Mattson, 
& Cerutis, 2009; Patel, Wilson, & Palmer, 2012; Rathe, Junker, 
Chesnutt, & Jansen, 2009; Reynolds, Aichelmann-Reidy, Branch-
Mays, & Gunsolley, 2003; Roselló-Camps et al., 2015; Sculean 
et al., 2015; Stoecklin-Wasmer et al., 2013; Troiano et al., 2017; 
Trombelli, Heitz-Mayfield, Needleman, Moles, & Scabbia, 2002; 
Yen, Tu, Chen, & Lu, 2014; Zanatta, Souza, Pinto, Antoniazzi, & 
Rösing, 2013; Zhou et al., 2018).
2.4 | Study selection
Study selection was conducted by independent reviewers in the fol-
lowing stages:
1. Initial screening of potentially suitable titles and abstracts against 
the inclusion criteria to identify potentially relevant papers (au-
thors L.B. and U.P.). Before initial screening, all the items found 
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through electronic and manual searches were grouped into a 
single list, excluding duplicates by means of EndNote™ soft-
ware (L.B.). Subsequently, two review authors (L.B. and U.P.) 
independently screened the titles and abstracts (when available) 
of all reports identified in the EndNote™ single list (step 1). 
When studies met the inclusion criteria or when insufficient 
data from abstracts for evaluating inclusion criteria were gained, 
the full article was obtained.
2. Eligibility of the full papers identified as possibly relevant in the initial 
screening (L.B., F.C., V.K., U.P.). Four review authors (L.B., F.C., V.K. 
and U.P.) independently assessed the full text of all studies of pos-
sible relevance.
Interrater agreement among examiners was calculated using the 
kappa score after article selection. The following outcomes were re-
ported, leading moderate to substantial reliability (Landis & Koch, 
1977):
Examiner 1 versus Examiner 2: K = 0.63 (95% CI from 0.52 to 
0.74)
Examiner 1 versus Examiner 3: K = 0.67 (95% CI from 0.57 to 
0.78)
Examiner 1 versus Examiner 4: K = 0.61 (95% CI from 0.49 to 
0.72)
Examiner 2 versus Examiner 3: K = 0.55 (95% CI from 0.43 to 
0.67)
Examiner 2 versus Examiner 4: K = 0.55 (95% CI from 0.43 to 
0.67)
Examiner 3 versus Examiner 4: K = 0.72 (95% CI from 0.63 to 
0.82)
When disagreement between the four reviewers was revealed, 
consensus was achieved by discussion between all reviewers (step 
2).
An attempt was made to contact authors of potentially relevant 
papers in order to obtain summary data, which may not have been 
reported in the published document and clarify potential inclusion 
of such papers.
2.5 | Data collection process and data items
All studies meeting the inclusion criteria then underwent quality 
assessment and data recording. A standardized specifically de-
signed data extraction form was used to record data from each 
included study, encompassing number of patients, demographics, 
definition and diagnosis of periodontitis, clinical methods (assess-
ment and treatment), follow-up duration, clinical and radiographic 
outcomes and patient-reported outcomes. Two review authors 
(L.B. and V.K.) independently extracted data. When disagree-
ment between the two reviewers was detected, consensus was 
achieved by discussion with the third reviewer/statistical advisor 
(M.N.).
2.6 | Study characteristics
Only RCTs, with or without a split-mouth design, were included in 
the systematic review.
CAL gain had to be expressed as mean clinical attachment level 
increase in millimetres of the treated sites of each study arm at fol-
low-up visit. PD reduction had to be expressed as mean periodontal 
probing depth reduction in millimetres of the treated sites of each 
study arm at follow-up visit. Rec had to be expressed as mean re-
cession in millimetres of the treated sites of each study arm at 
baseline and follow-up visits. Radiographic BG (bone gain) had to be 
expressed as mean intra-bony component decrease in millimetres of 
the treated intra-bony defects of each study arm at follow-up visit. 
Tooth loss had to be expressed as the number or the percentage of 
treated teeth of each considered study arm that resulted missing (ex-
tracted) at the follow-up visit. Pocket “closure” had to be reported as 
the presence of PD ≤ 4 mm at experimental site at study follow-up. 
PROMs (patient-reported outcome measures) and AE (adverse events) 
had to be described at least in a narrative form.
2.7 | Risk of bias in individual studies
The quality assessment of the included studies was independently 
performed in a duplicate form by two review authors (L.B. and M.N.) 
through risk of bias analysis as it could impact on the overall results 
and conclusions (“Systematic reviews, CRD's guidance for undertak-
ing reviews in health care,” University of York, 2008). The Cochrane 
Collaboration's tool was used for assessing risk of bias (Higgins & 
Green, 2011) (Figure 2).
Briefly, seven domains (sequence generation, allocation conceal-
ment, blinding of the outcome assessor, blinding of participants and 
personnel, incomplete outcome data, selective outcome reporting 
and other bias) were considered and included in a specific table.
Risk of bias in the included studies was categorized as below:
A Low risk of bias (plausible bias unlikely to seriously alter the re-
sults) if all criteria were met.
B Unclear risk of bias (plausible bias that raises some doubt about 
the results) if one or more criteria were partly met.
C High risk of bias (plausible bias that seriously weakens confidence 
in the results) if one or more criteria were not met.
2.8 | Summary measures and planned 
method of analysis
Studies were initially narratively summarized by chief characteris-
tics and according to type of regenerative surgery, for example GTR, 
bone filler material and type of membrane. A meta-analysis was con-
sidered appropriate and was performed in the presence of at least 
two studies of similar design. Mean differences were used for CAL 
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gain, PD reduction, Rec reduction (RecRed), bone gain, aesthetic and 
functional satisfaction. The odds ratio of tooth loss and for compli-
cations was used as a summary measure.
The variables were registered at patient level. In each patient, 
only one tooth per technique was assessed. When studies with mul-
tiple teeth were identified, the presence of individual patient data 
(IPD) was checked and the mean of the multiple sites was used for 
the analysis. If the IPD were not reported in the study, the number 
of patients was used in the meta-analysis.
Forest plots were produced when appropriate to graphically rep-
resent the difference in outcomes between groups using the patient 
as the analysis unit.
The techniques described by Elbourne et al. were used to cal-
culate the standard error of the difference in split-mouth studies, 
where the appropriate data were not presented (Elbourne et al., 
2002).
Meta-analyses were performed on an intention-to-treat basis 
using the generic inverse variance method with random-effect mod-
els. Ninety-five per cent confidence intervals for each outcome vari-
able were calculated. The significance of any discrepancies in the 
estimates of the treatment effects from different trials was assessed 
by means of the Cochran test for heterogeneity and the I2 statistic, 
which describes the percentage total variation across studies that is 
due to heterogeneity rather than change. The suggested interpreta-
tion of I2 is as follows: 0%–40% may represent low heterogeneity, 
30%–60% may represent moderate heterogeneity, 50%–90% may 
represent substantial heterogeneity and 75%–100% considerable 
heterogeneity (Higgins & Green, 2011). Funnel plots and Egger's test 
were planned to explore the presence of publication bias if at least 
10 studies were included in the meta-analysis (Song, Hooper, & Loke, 
2013; Sterne, Egger, & Moher, 2008). Sensitivity analysis was also 
planned considering only studies in the single meta-analysis at low 
risk of bias.
The statistical analyses were carried out using the RevMan soft-
ware version 5.3 (Copenhagen: The Nordic Cochrane Centre, The 
Cochrane Collaboration, 2014) by a single reviewer (MN).
2.9 | Evaluation of the strength of evidence
Evidence regarding provided by RTCs was rated using different lev-
els of methodological strength modified from GRADE (Grading of 
Recommendations Assessments Development and Evaluation) (Guyatt 
et al., 2008). Three different strength of evidence were considered:
• High: At least 3 RCTs at low risk of bias and low heterogeneity.
• Moderate: More than 1 RCT and at least 1 RCT at low risk of bias 
and low heterogeneity.
• Low: Lack of RCTs or RCTs at high risk of bias or high heterogeneity.
3  | RESULTS
3.1 | Study selection
The search results are presented in Figure 1.
The electronic search in MEDLINE (by PubMed), in the Cochrane 
Collaboration databases and in Scopus provided, respectively, 646, 
766 and 1,544 articles published until January 2019. After grouping 
into a single list and discarding duplicates, 1,012 articles were iden-
tified by electronic search.
The hand searching found 421 articles, 7 of which were not 
found by the electronic search.
The search in the reference lists of included studies and previous 
systematic reviews or guidelines provided 10 additional articles not 
found by electronic and hand searching.
F I G U R E  1   Literature search process 
and results
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The search of the “grey literature” (unpublished data) by e-mail 
contact with all the authors of the identified studies and clinical ex-
perts or researchers in the field of periodontal surgery did not pro-
vide additional data.
Finally, by merging the literature searches (electronic, manual 
and unpublished data searches), 1,029 articles (1,012 by electronic, 
7 by hand search and 10 by reference lists) were selected.
Subsequently, by first-stage reading all titles and abstracts, 184 
articles were screened as potentially relevant papers.
The full-text reading of the 184 articles allowed the selec-
tion of 88 articles (79 studies) that met the inclusion criteria of 
this systematic review and the exclusion of 96 articles from the 
analysis. Rejected studies at this stage are listed in Appendix S4 
(Characteristics of excluded studies), and the reason for exclusion 
was recorded.
3.2 | Study characteristics
All 79 studies (88 articles) included in the systematic review are pre-
sented in Tables 1 and 2. All included studies were published between 
1990 and 2019 and accounted for 3,042 patients and 3,612 intra-bony 
defects. Out of the 79 studies, 11 reported data after 3 years of fol-
low-up, 8 studies between 1 and 3 years of follow-up, and the residual 
60 studies have a follow-up of 1 year. The use of systemic antibiotics 
was reported in 58 studies, while in 10 RTCs, no systemic antibiotics 
were used. In the residual 11 studies, no information was reported.
3.3 | Source of funding
Regarding the source of funding, 15 included studies received pri-
vate financial support, 17 public support and 12 combination of 
public and private funding. In addition, 2 studies reported no fund-
ing, whereas the majority (33 studies) did not report the source of 
funding.
3.4 | Results of the analyses
Based on available studies, the following comparisons were consid-
ered (at least 2 available studies for each comparison):
 1. Open flap for debridement (OFD) versus all regenerative pro-
cedures (RP)
 2. OFD versus OFD + enamel matrix derivative (EMD)
 3. OFD versus OFD + guided tissue regeneration (GTR)
 4. OFD versus OFD + deproteinized bovine bone mineral 
(DBBM) + GTR
 5. OFD versus OFD + platelet-rich fibrin (PRF)
 6. OFD + demineralized freeze-dried bone allograft (DFDBA) ver-
sus OFD + DFDBA + platelet-rich plasma (PRP)
 7. OFD + DBBM versus OFD + DBBM + other
 8. OFD + GTR versus OFD + EMD
 9. OFD + EMD versus OFD + EMD + other
 10. OFD + EMD versus OFD + filler
 11. OFD + non-resorbable GTR (GTR-NR) versus OFD + resorbable 
GTR (GTR-R)
 12. OFD + filler + GTR versus OFD + filler + GTR + PRP
 13. OFD + GTR versus OFD + GTR + filler
Clinical outcomes from a total of 50 RCTs (52 articles) were 
included in the meta-analyses. Table 3 reports the results of me-
ta-analyses for all investigated variables including CAL, PD reduc-
tion, recession and bone gain.
The main results of the meta-analyses can be summarized as:
• OFD versus all RP: Regenerative procedures resulted in improved 
CAL gain, greater PD and bone gain compared with OFD alone. 
Moderate to substantial heterogeneity in the size of the adjunc-
tive effect was observed. This could be partly explained by the 
use of specific biomaterials or flap designs.
• OFD versus EMD + OFD: EMD results in greater CAL gain, PD 
reduction and bone gain compared with OFD alone. RecRed is not 
significantly different between the two treatments. Substantial 
to considerable heterogeneity is present for the variables. In part, 
the heterogeneity could be due to the presence or not of the pla-
cebo in the control group.
• OFD versus OFD + GTR: GTR results in greater CAL gain and 
PD reduction compared with OFD alone. RecRed and bone gain 
are not significantly different between the two interventions. 
Moderate to substantial heterogeneity is present. In part, the het-
erogeneity could be due to the presence of resorbable or non-re-
sorbable membranes.
• OFD versus OFD + DBBM + GTR: OFD + DBBM + GTR results in 
greater CAL gain, PD reduction, RecRed and CAL gain stability in 
the long term compared with OFD. Moderate to substantial het-
erogeneity is present. In part, the heterogeneity could be due to 
the presence of OFD or papilla preservation flaps (PPF).
• OFD versus OFD + PRF: OFD + PRF results in greater CAL gain 
and PD reduction compared with OFD. Substantial to consider-
able heterogeneity is present.
• OFD + DFDBA versus OFD + DFDBA + PRP: OFD + DFDBA + PRP 
results in greater CAL gain, RecRed and bone gain compared with 
OFD + DFDBA. PD reduction is not significantly different be-
tween the two treatments. Low to substantial heterogeneity is 
present. In part, the heterogeneity could be due to the presence 
of PRP or PRF.
• OFD + GTR versus OFD + EMD: CAL gain, PD reduction 
and RecRed are not significantly different when comparing 
OFD + GTR versus OFD + EMD. Moderate to substantial het-
erogeneity is present. For PD reduction, the heterogeneity 
could be due to the presence of resorbable or non-resorbable 
membranes.
• OFD + EMD versus OFD + EMD + Other: OFD + EMD + Other 
results in greater CAL gain, PD reduction and bone gain compared 
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with to OFD + EMD. RecRed is not significantly different between 
the two interventions. Low to moderate heterogeneity is pres-
ent. Assessing the different materials added to OFD + EMD, only 
DBBM is significant for CAL gain and PD reduction, while HA/
bTCP is significant for bone gain.
• OFD + GTR-NR versus OFD + GTR-R: CAL gain, PD reduction and 
RecRed are not significantly different comparing OFD + GTR-NR 
versus OFD + GTR-R. The heterogeneity was low.
Sensitivity analysis was also performed considering only studies 
in the single meta-analysis at low risk of bias.
The following meta-analyses were than available for this 
evaluation:
• OFD versus OFD + EMD, one RCT, (De Leonardis & Paolantonio, 
2013)
• OFD versus OFD + GTR, three RCTs (2 studies by Loos et al., 2002 
and Stavropoulos, Karring, Kostopoulos, & Karring, 2003)
• OFD versus OFD + DBBM + GTR, one RCT (Stavropoulos et al., 
2003)
• OFD + GTR versus OFD + EMD, two RCTs (Iorio Ghezzi, 
Ferrantino, Bernandini, Lencioni, & Masiero, 2016; Siciliano et al., 
2011)
• OFD + EMD versus OFD + EMD + Other, three RCTs (De 
Leonardis & Paolantonio, 2013; Meyle et al., 2011; Sipos, Loos, 
Abbas, Timmerman, & Velden, 2005)
Interestingly, sensitivity analysis did not change the results 
of primary analysis, apart from the comparison OFD versus 
OFD + GTR, which showed no significant difference between 
treatments.
4  | TOOTH LOSS
Very limited data are available for the tooth loss variable. Only 
1 tooth in the papilla preservation flap group was lost in Tonetti, 
Cortellini, et al. (2004)) due to periodontal reason in a 12-month 
follow-up (Tonetti, Cortellini, et al., 2004). Considering the long-
term observation, after 7 years of follow-up, 2 teeth were lost 
due to periodontal reason out of 36 treated with a GTR proce-
dure (Stavropoulos & Karring, 2010). Similarly, patients treated 
with OFD + AB with or without a membrane lost one tooth on 




Only very few studies reported PROMs, and no meta-analysis was 
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(2004) reported no difference for post-operative discomfort and num-
ber of analgesic tablets when compared to PPF alone. Similar results 
were reported when a resorbable membrane (GTR-R) was used with a 
PPF procedure (Cortellini et al., 2001). These data are scarce and not 
conclusive, even if the influence of EMD or resorbable membrane on 
post-operative discomfort seems to be minimal compared with OFD.
4.1.2 | Adverse events
No authors reported serious adverse events in the included studies. 
Due to heterogeneity of the techniques and data, no meta-analysis 
was possible. A common reported complication was the exposure of 
non-resorbable membranes. This was frequently reported in 4 stud-
ies testing GTR-NR (Crea, Dassatti, Hoffmann, Zafiropoulos, & Deli, 
2008; Siciliano et al., 2011; Zucchelli, Bernardi, Montebugnoli, & De, 
2002; Zybutz, Laurell, Rapoport, & Persson, 2000), with a rate of 
exposure ranging from 15% to 66% during the first 6 post-operative 
weeks. Similarly, the studies testing resorbable membranes (GTR-R) 
reported a rate of exposure ranging from 20% (Sculean et al., 2003; 
Siciliano et al., 2014) to 62% (Sanz et al., 2004) and 86% (Zybutz et 
al., 2000). Usually, the exposure for resorbable membranes is mini-
mal with no serious effect on the clinical outcomes. There is also no 
definitive evidence regarding the complexity of regenerative proce-
dure and the rate of exposure. A series of studies tested different 
combinations using bTCP, DBBM and both GTR-R and GTR-NR (Döri 
et al., 2007a, 2007b; Döri, Huszár, et al., 2008; Döri, Nikolidakis, et 
al., 2008) and described higher rate of complications when using 
bTCP + GTR-NR (Döri, Huszár, et al., 2008).
4.1.3 | Pocket “closure” (PD ≤ 4 mm)
Only a few studies reported data on “pocket closure.” Included stud-
ies seem to show an increased probability of pocket closure for GTR 
procedures (Cortellini et al., 2001; Siciliano et al., 2011; Zucchelli et 
al., 2002) compared to OFD alone. However, in one no difference 
was reported between GTR and OFD (Tonetti et al., 1998).
4.1.4 | Risk of bias
Out of the 79 included studies, 14 were rated at high risk of bias, 55 
at unclear and only 10 at low risk of bias. Among the seven domains, 
the lack of blinding of the outcome assessor (18%) and incomplete 
outcome data (5%) were the most frequent sources of bias (Figure 2 
and Appendix S5).
5  | DISCUSSION
The focused question of this systematic review was “Does regen-
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TA B L E  3   Meta-analysis results
Comparisons between OFD and regenerative procedures
Comparison CAL gain PD reduction REC Bone gain
1. OFD vs. OFD + RP 
(regenerative 
procedures)
Better OFD + RP Better OFD + RP No SSD Better OFD + RP
p < .00001 p < .00001 p < .04 p < .0006
MD = 1.34 MD = 1.20 MD = 0.14 MD = 1.57
95% CI: 0.95, 1.73 95% CI: 0.85, 1.55 95% CI: 0.00, 0.28 95% CI: 0.67, 2.47
I2 = 86% I2 = 82% I2 = 39% I2 = 93%
22 studies
RoB: 4 low, 13 unclear, 5 
high
Low strength of evidence
22 studies
RoB: 4 low, 13 unclear, 5 
high
Low strength of evidence
19 studies
RoB: 4 low, 10 unclear, 5 
high
Low strength of evidence
6 studies
RoB: 2 low, 3 unclear, 1 
high
Low strength of evidence
2. OFD vs. OFD + EMD Better OFD + EMD Better OFD + EMD No SSD Better OFD + EMD
p < .00001 p < .00001 p = .19 p < .0004
MD = 1.31 MD = 1.04 MD = 0.18 MD = 1.70
95% CI: 0.86, 1.86 95% CI: 0.85, 1.22 95% CI: −0.09, 0.44 95% CI: 0.76, 2.64
I2 = 79% I2 = 74% I2 = 68% I2 = 91%
10 studies
RoB: 1 low, 7 unclear, 3 high
Low strength of evidence
10 studies
RoB: 1 low, 7 unclear, 3 high
Low strength of evidence
8 studies
RoB: 1 low, 5 unclear, 3 
high
Low strength of evidence
4 studies
RoB: 1 low, 2 unclear, 1 
high
Low strength of evidence
Sub-Group
2.1 OFD Better OFD + EMD Better OFD + EMD No SSD No data
p < .00001 p < .00001 p = .42
MD = 3.30 MD = 3.40 MD = −0.30
95% CI: 2.12, 4.48 95% CI: 2.13, 4.67 95% CI: −1.03, 0.43
I2 = not applicable I2 = not applicable I2 = not applicable
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
2.2 PPF Better PPF + EMD Better PPF + EMD Better PPF + EMD Better PPF + EMD
p < .00001 p < .00001 p = .002 p < .00001
MD = 1.46 MD = 1.09 MD = 0.30 MD = 2.08
95% CI: 1.01, 1.91 95% CI: 0.87, 1.32 95% CI: −0.03, 0.63 95% CI: 1.34, 2.82
I2 = 69% I2 = 72% I2 = 76% I2 = 73%
6 studies
RoB: 1 low, 4 unclear, 1 high
Low strength of evidence
6 studies
RoB: 1 low, 4 unclear, 1 high
Low strength of evidence
5 studies
RoB: 1 low, 3 unclear, 1 
high
Low strength of evidence
2 studies
RoB: 1 low, 4 unclear
Low strength of evidence
2.3 OFD + Placebo Better OFD + EMD Better OFD + EMD No SSD Better OFD + EMD
p = .001 p < .0001 p = 1.00 p < .00001
MD = 0.69 MD = 0.79 MD = 0.00 MD = 2.60
95% CI: 0.27, 1.11 95% CI: 0.42, 1.16 95% CI: −0.43, 0.43 95% CI: 1.95, 3.25
I2 = 0% I2 = 0% I2 = Not applicable I2 = not applicable
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
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2.4 PPF + placebo No SSD No SSD No SSD No SSD
p < .82 p = .54 p = .61 p = 1.00
MD = 0.10 MD = 0.30 MD = −0.20 MD = 0.00
95% CI: −0.74, 0.94 95% CI: −0.66, 1.26 95% CI: −0.96, 0.56 95% CI: −0.84, 0.84
I2 = not applicable I2 = 82.8% I2 = 68% I2 = not applicable
1 study
RoB: 1 high
Low strength of evidence
1 study
RoB: 1 high
Low strength of evidence
1 study
RoB: 1 high
Low strength of evidence
1 study
RoB: 1 high
Low strength of evidence
3. OFD vs. OFD + GTR Better OFD + GTR Better OFD + GTR No SSD No SSD
p = .0007 p = .003 p = .76 p = .34
MD = 1.15 MD = 1.24 MD = −0.04 MD = 0.91
95% CI: 0.48, 1,82 95% CI: 0.41, 2.07 95% CI: −0.27, 0.20 95% CI: −0.95, 2.77
I2 = 82% I2 = 87% I2 = 23% I2 = 88%
9 studies
RoB: 3 low, 4 unclear, 2 high
Low strength of evidence
9 studies
RoB: 3 low, 4 unclear, 2 high
Low strength of evidence
9 studies
RoB: 3 low, 4 unclear, 2 
high
Moderate strength of 
evidence
2 studies
RoB: 1 low, 1 unclear
Low strength of evidence
Sub-Group
3.1 Not resorbable 
OFD
Better OFD + GTR-NR Better OFD + GTR-NR Better OFD + GTR-NR No data
p = .04 p = .02 p = .05
MD = 2.36 MD = 3.14 MD = −0.43
95% CI: 0.11, 4.61 95% CI: 0.49, 5.78 95% CI: −0.85, 0.00
I2 = 87% I2 = 93% I2 = 0%
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
3.2 Not resorbable PPF Better PPF + GTR-NR Better PPF + GTR-NR No SSD No data
p < .00001 p < .00001 p = .19
MD = 2.30 MD = 2.00 MD = 0.30
95% CI: 1.65, 2.95 95% CI: 1.33, 2.67 95% CI: −0.15, 0.75
I2 = not applicable I2 = not applicable I2 = not applicable
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
3.3 Resorbable OFD No SSD No SSD No SSD No SSD
p = .78 p = .98 p = .90 p = 1.00
MD = 0.16 MD = −0.01 MD = 0.05 MD = 0.00
95% CI: −0.92, 1.23 95% CI: −0.59, 0.58 95% CI: −0.72, 0.82 95% CI: −0.71, 0.71
I2 = 70% I2 = 0% I2 = 52% I2 = not applicable
3 studies
RoB: 2 low, 1 unclear
Low strength of evidence
3 studies
RoB: 2 low, 1 unclear
Moderate strength of 
evidence
3 studies
RoB: 2 low, 1 unclear




Low strength of evidence
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3.4 Resorbable PPF Better PPF + GTR-R Better PPF + GTR-R No SSD Better PPF + GTR-R
p < .0001 p < .0001 p = .76 p = .0004
MD = 0.91 MD = 0.91 MD = 0.02 MD = 1.90
95% CI: 0.50, 1.32 95% CI: 0.46, 1.36 95% CI: −0.27, 0.31 95% CI: 0.84, 2.96
I2 = 0% I2 = 0% I2 = 0% I2 = not applicable
3 studies
RoB: 1 low, 2 high
Moderate strength of 
evidence
3 studies
RoB: 1 low, 2 high
Moderate strength of 
evidence
3 study
RoB: 1 low, 2 high




Low strength of evidence
4. OFD vs. 
OFD + DBBM + GTR
Better OFD + DBBM + GTR Better OFD + DBBM + GTR Better 
OFD + DBBM + GTR
No data
p = .004 p .002 p = .01
MD = 1.50 MD = 1.13 MD = 0.36
95% CI: 0.66, 2.34 95% CI: 0.42, 1.84 95% CI: 0.07, 0.64
I2 = 71% I2 = 60% I2 = 0%
4 studies
RoB: 1 low, 2 unclear, 1 high
Low strength of evidence
4 studies
RoB: 1 low, 2 unclear, 1 high
Low strength of evidence
4 studies
RoB: 1 low, 2 unclear, 1 
high
Moderate strength of 
evidence
Sub.Group
4.1 OFD Better OFD + DBBM + GTR Better OFD + DBBM + GTR No SSD No data
p < .00001 p < .00001 p = .18
MD = 2.11 MD = 1.72 MD = 0.34
95% CI: 1.52, 2.71 95% CI: 1.05, 2.38 95% CI: −0.16, 0.85
I2 = 0% I2 = 0% I2 = 0%
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
4.2 PPF Better PPF + DBBM + GTR Better PPF + DBBM + GTR Better PPF + DBBM + GTR No data
p = .003 p < .03 p = .04
MD = 0.82 MD = 0.58, MD = 0.36
95% CI: 0.28, 1.36 95% CI: 0.05, 1.11 95% CI: 0.01, 0.71
I2 = 0% I2 = 0% I2 = 0%
2 studies
RoB: 1 low, 1 high
Moderate strength of 
evidence
2 studies
RoB: 1 low, 1 high
Moderate strength of 
evidence
2 studies
RoB: 1 low, 1 high
Moderate strength of 
evidence
5. OFD vs. OFD + PRF Better OFD + PRF Better OFD + PRF No data No data
p = .01 p < .00001
MD = 2.63 MD = 2.29
95% CI: 0.60, 4.65 95% CI: 1.67, 2.92
I2 = 96% I2 = 47%
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
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6. OFD + DFDBA vs. 
OFD + DFDBA + PRP
Better 
OFD + DFDBA + PRP
NO SSD Better 
OFD + DFDBA + PRP
Better 
OFD + DFDBA + PRP
p < .00001 p < .10 p < .00001 p < .00001
MD = 0.94 MD = 0.45 MD = 0.59 MD = 0.81
95% CI: 0.65, 1.24 95% CI: −0.08, 0.98 95% CI: 0.40, 0.78 95% CI: 0.54, 1.08
I2 = 40% I2 = 80% I2 = 0% I2 = 40%
3 studies
RoB: 3 unclear
Low strength of evidence
3 studies
RoB: 3 unclear
Low strength of evidence
3 studies
RoB: 3 unclear
Low strength of evidence
3 studies
RoB: 3 unclear
Low strength of evidence
Sub-Group
6.1 PRP Better 
OFD + DFDBA + PRP
No SSD Better 
OFD + DFDBA + PRP
Better 
OFD + DFDBA + PRP
p < .00001 p < .38 p = .03 p < .00001
MD = 0.78 MD = 0.48 MD = 0.55 MD = 0.65
95% CI: 0.52, 1.05 95% CI: −0.59, 1.55 95% CI: 0.06, 1.04 95% CI: 0.41, 0.90
I2 = 0% I2 = 84% I2 = 36% I2 = 0%
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
6.2 PRF Better 
OFD + DFDBA + PRF
Better 
OFD + DFDBA + PRF
Better 
OFD + DFDBA + PRF
Better 
OFD + DFDBA + PRF
p < .00001 p = .0006 p < .0002 p < .00001
MD = 1.12 MD = 0.55 MD = 0.53 MD = 1.01
95% CI: 0.81, 1.43 95% CI: 0.24, 0.86 95% CI: 0.26, 0.80 95% CI: 0.72, 1.30
I2 = not applicable I2 = not applicable I2 = not applicable I2 = not applicable
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
7. OFD + DBBM vs. 
OFD + DBBM + Other
No SSD No SSD No SSD No data
p = .78 p = .40 p = .11
MD = −0.13 MD = −0.39 MD = 0.50
95% CI: −1.08, 0.81 95% CI: −1.29, 0.52 95% CI: −0.11, 1–12
I2 = 0% I2 = 0% I2 = 6%
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
Sub-Group
7.1 EMD No SSD No SSD Better 
OFD + DBBM + EMD
No data
p = .84 p = .27 p = .05
MD = −0.20 MD = −0.80 MD = 0.70
95% CI: −1.81, 1.41 95% CI: −2.21, 0.61 95% CI: 0.01, 1.39
I2 = not applicable I2 = not applicable I2 = not applicable
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
TA B L E  3   (Continued)
(Continues)
338  |     NIBALI et AL.
Comparations between regenerative procedures
Comparison CAL gain PD reduction REC Bone gain
7.2 PRP No SSD No SSD No SSD No data
p = .87 p = .87 p = 1.00
MD = −0.10 MD = −0.10 MD = 0.00
95% CI: −1.28, 1.08 95% CI: −1.28, 1.08 95% CI: −1.14, 1.14
I2 = not applicable I2 = not applicabe I2 = not applicable
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
8. OFD + GTR vs. 
OFD + EMD
No SSD No SSD No SSD No data
p = .51 p = .21 p = .17
MD = −0.15 MD = −0.44 MD = 0.20
95% CI: −0.58, 0.29 95% CI: −1.12, 0.24 95% CI: −0.09, 0.49
I2 = 56% I2 = 82% I2 = 34%
8 studies
RoB: 2 low, 3 unclear, 3 
high
Low strength of evidence
8 studies
RoB: 2 low, 3 unclear, 3 
high
Low strength of evidence
5 studies
RoB: 2 low, 1 unclear, 2 
high
Moderate strength of 
evidence
Sub-Group
8.1 Non resorbable 
GTR-RN
No SSD Better OFD + GTR-NR No SSD No data
p = .22 p = .03 p = .56
MD = −0.47 MD = −1.06 MD = 0.23
95% CI: −1.22, 0.29 95% CI: −2.04, −0.08 95% CI: 0.55, 1.01
I2 = 73% I2 = 85% I2 = 80%
4 studies
RoB: 1 low, 2 unclear, 1 
high
Low strength of evidence
4 studies
RoB: 1 low, 2 unclear, 1 
high
Low strength of evidence
2 studies
RoB: 1 low, 1 unclear
Low strength of evidence
8.2 Resorbable GTR-R No SSD No SSD No SSD No data
p = .74 p = .26 p = .65
MD = 0.13 MD = 0.28 MD = 0.10
95% CI: −0.64, 0.91 95% CI: −0.21, 0.76 95% CI: −0.33, 0.53
I2 = 53% I2 = 0% I2 = not applicable
2 studies
RoB: 1 unclear, 1 high
Low strength of evidence
2 studies
RoB: 1 unclear, 1 high
Low strength of evidence
1 study
RoB: 1 high
Low strength of evidence
8.3 Resorbable + DBBM No SSD No SSD No SSD No data
p = .61 p = .67 p = .57
MD = 0.19 MD = 0.20 MD = 0.14
95% CI: −0.54, 0.93 95% CI: −0.72, 1.12 95% CI: −0.33, 0.61
I2 = 0% I2 = 82% I2 = 0%
2 studies
RoB: 1 low, 1 high
Moderate strength of 
evidence
2 studies
RoB: 1 low, 1 high
Low strength of evidence
2 studies
RoB: 1 low, 1 high
Moderate strength of 
evidence
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9. OFD + EMD vs. 
OFD + EMD + Other
Better 
OFD + EMD + Other
Better 
OFD + EMD + Other
No SSD No data
p = .005 p = .001 p = .20
MD = 0.41 MD = 0.40 MD = 0.15
95% CI: 0.13, 0.69 95% CI: 0.15, 0.64 95% CI: −0.08, 0.38
I2 = 36% I2 = 32% I2 = 50%
10 studies
RoB: 3 low, 6 unclear, 1 
high
Moderate strength of 
evidence
10 studies
RoB: 3 low, 6 unclear, 1 
high
Moderate strength of 
evidence
10 studies
RoB: 3 low, 6 unclear, 1 
high
Moderate strength of 
evidence
Sub-Group
9.1 AB (Autogenous bone) No SSD No SSD No SSD No data
p = .48 p = .61 p = .56
MD = 0.38 MD = 0.37 MD = 0.29
95% CI: −0.67, 1.43 95% CI: −1.07, 1.82 95% CI: −0.69, 1.27
I2 = 62% I2 = 79% I2 = 84%
2 studies
RoB: 1 unclear, 1 high
Low strength of evidence
2 studies
RoB: 1 unclear, 1 high
Low strength of evidence
2 studies
RoB: 1 unclear, 1 high
Low strength of evidence
9.2 bTCP No SSD No SSD No SSD No data
p = .35 p = .63 p = 1.00
MD = 0.30 MD = 0.20 MD = 0.00
95% CI: −0.33, 0.93 95% CI: −0.60, 1.00 95% CI: −0.76, 0.76
I2 = not applicable I2 = not applicable I2 = not applicable
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
9.3 HA/bTCP No SSD No SSD No SSD Better OFD + EMD + HA/
bTCP
p = .58 p = .12 p = .13 p < 0.00001
MD = 0.21 MD = 0.32 MD = 0.13 MD = 0.67
95% CI: −0.52, 0.94 95% CI: −0.08, 0.72 95% CI: −0.04, 0.29 95% CI: 0.40, 0.94
I2 = 61% I2 = 19% I2 = 0% I2 = 0%
3 studies
RoB: 2 low, 1 unclear
Low strength of evidence
3 studies
RoB: 2 low, 1 unclear
Moderate strength of 
evidence
3 studies
RoB: 2 low, 1 unclear
Moderate strength of 
evidence
3 studies
RoB: 2 low, 1 unclear
Moderate strength of 
evidence
9.4 Bioactive Glass (BG) No SSD No SSD No SSD No data
p = .27 p = .63 p = .46
MD = −0.70 MD = −0.30 MD = −0.20
95% CI: −1.95, 0.55 95% CI: −1.53, 0.93 95% CI: −0.73, 0.33
I2 = not applicable I2 = not applicable I2 = not applicable
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
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9.5 DBBM Better 
OFD + EMD + DBBM
Better 
OFD + EMD + DBBM
Better 
OFD + EMD + DBBM
No data
p = .0009 p = .01 p = .0004
MD = 0.90 MD = 0.40 MD = 0.50
95% CI: 0.37, 1.43 95% CI: 0.09, 0.71 95% CI: 0.23, 0.77
I2 = not applicable I2 = not applicable I2 = not applicable
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
9.6 GTR No SSD No SSD No SSD No data
p = .19 p = .25 p = .82
MD = 0.38 MD = 0.36 MD = 0.18
95% CI: −0.18, 0.93 95% CI: −0.25, 0.97 95% CI: −1.33, 1.69
I2 = 0% I2 = 0% I2 = not applicable
2 studies
RoB: 1 low, 1 unclear
Moderate strength of 
evidence
2 studies
RoB: 1 low, 1 unclear




Low strength of evidence
10. OFD + EMD vs. 
OFD + Graft
No SSD No SSD No SSD No data
p = .98 p = .56 p = .30
MD = 0.02 MD = −0.23 MD = 0.78
95% CI: −1.25, 1.29 95% CI: −1.01, 0.55 95% CI: −0.69, 2.24
I2 = 75% I2 = 0% I2 = 78%
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
Sub-Group
10.1 Bioactive Glass (BG) No SSD No SSD Better OFD + BG No data
p = .09 p = .86 p = .008
MD = 0.60 MD = 0.10 MD = 1.60
95% CI: −0.09, 1.29 95% CI: −0.98, 1.18 95% CI: 0.42, 2.78
I2 = not applicable I2 = not applicable I2 = not applicable
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
10.2 HA No SSD No SSD No SSD No data
p = .20 p = .30 p = .79
MD = −0.70 MD = −0.60 MD = 0.10
95% CI: −1.78, 0.38 95% CI: −1.74, 0.54 95% CI: −0.63, 0.83
I2 = not applicable I2 = not applicable I2 = not applicable
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
TA B L E  3   (Continued)
(Continues)
     |  341NIBALI et AL.
Comparations between regenerative procedures
Comparison CAL gain PD reduction REC Bone gain
11. OFD + GTR-NR vs. 
OFD + GTR-R
No SSD No SSD No SSD No data
p = .96 p = .76 p = .34
MD = 0.02 MD = 0.16 MD = 0.25
95% CI: −0.91, 0.96 95% CI: −0.80, 1.12 95% CI: −0.26, 0.76
I2 = 0% I2 = 0% I2 = 0%
2 studies
RoB: 1 unclear, 1 high
Low strength of evidence
2 studies
RoB: 1 unclear, 1 high
Low strength of evidence
2 studies
RoB: 1 unclear, 1 high
Low strength of evidence
12. OFD + Graft + GTR vs. 
OFD + Graft + GTR + PRP
No SSD No SSD No SSD No data
p = .86 p = .12 p = .87
MD = 0.03 MD = 0.26 MD = 0.03
95% CI: −0.32, 0.39 95% CI: −0.07. 0.59 95% CI: −0.28, 0.33
I2 = 0% I2 = 0% I2 = 0%
4 studies
RoB: 4 unclear
Low strength of evidence
4 studies
RoB: 4 unclear
Low strength of evidence
4 studies
RoB: 4 unclear
Low strength of evidence
Sub-Group
12.1 bTCP No SSD No SSD No SSD No data
p = .83 p = .06 p = .73
MD = 0.05 MD = 0.36 MD = −0.07
95% CI: −0.41, 0.52 95% CI: −0.01, 0.73 95% CI: −0.49, 0.34
I2 = 0% I2 = 0% I2 = 0%
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
12.2 DBBM No SSD No SSD No SSD No data
p = .99 p = .76 p = .54
MD = 0.00 MD = −0.11 MD = 0.14
95% CI: −0.54, 0.55 95% CI: −0.83, 0.61 95% CI: −0.30, 0.58
I2 = 0% I2 = 0% I2 = 0%
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
13. OFD + GTR vs. 
OFD + GTR + Graft
No SSD No SSD No SSD No data
p = 1.00 p = .48 p = .08
MD = 0.00 MD = −0.33 MD = 0.48
95% CI: −1.99, 1.99 95% CI: −1.23, 0.58 95% CI: −0.05, 1.01
I2 = 92% I2 = 60% I2 = 0%
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
2 studies
RoB: 2 unclear
Low strength of evidence
Sub-Group
13.1 DFDBA Better OFD + GTR Better OFD + GTR No SSD No data
p = .003 p = .04 p = .53
MD = −0.98 MD = −0.75 MD = 0.23
TA B L E  3   (Continued)
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measured as probing pocket depth (PD) reduction, clinical attachment 
level (CAL) gain, recession (Rec) and radiographic bone gain (BG) in peri-
odontitis patients compared with access flap?” A total of 79 RCTs, cov-
ering data on 3,042 patients, and a total of 3,612 intra-bony defects 
were included in this SR. The overall outcomes showed that regen-
erative procedures, mainly based on the use of EMD or barriers, pro-
vided improved clinical outcomes 12 months after surgery compared 
with flap surgery alone.
A preliminary, large meta-analysis clustered all studies perform-
ing regenerative procures versus OFD alone. A total of 22 RCTs 
covering 1,182 teeth in 1,000 patients were considered. All RP re-
sulted in improved CAL gain (1.34 mm; 0.95–1.73) and greater PD 
(1.20 mm; 0.85–1.55) compared with OFD alone. Probably due to the 
variability in terms of specific biomaterials or flap designs, a moder-
ate to substantial heterogeneity in the size of the adjunctive effect 
was observed. This overall body of evidence, however, showed the 
superiority of RP in treating infrabony defects, thus decreasing the 
risk of disease progression and tooth loss in the long term when a 
regular support periodontal therapy is performed (Cortellini, Buti, 
Pini Prato, & Tonetti, 2017; Silvestri, Rasperini, & Milani, 2011).
A consistent number of RCTs investigated the effect of EMDs 
in the treatment of intra-bony defects compared with flap surgery 
alone, reporting data on a total of 487 defects (Figure 3). These data 
demonstrated higher benefits at 12 months when EMD was used, in 
terms of CAL gain (1.31 mm; 0.86–1.86; low strength of evidence) 
and PD reduction (1.04 mm; 0.85–1.22; low strength of evidence). 
The present outcome confirms the observation of a large multicentre 
study where EMD was applied in conjunction with PPF (Tonetti et al., 
2002). In this study, higher efficacy of regeneration was observed in 
non-smokers and for defects with a predominantly 3-wall anatomy, 
thus suggesting an effective interaction between biologicals and de-
fect configuration (Tsitoura et al., 2004). Interestingly, in this SR the 
addition of EMD was associated with higher radiographic bone fill 
than OFD alone (1.70 mm; 0.76–2.64 mm), leading to a positive ef-
fect in changing bone defect configuration. No significant difference 
in the recession of the gingival margin at the last study follow-up 
Comparations between regenerative procedures
Comparison CAL gain PD reduction REC Bone gain
95% CI: −1.63, −0.33 95% CI: −1.48, −0.02 95% CI: −0.50, 0.96
I2 = not applicable I2 = not applicable I2 = not applicable
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
13.2 DBBM Better 
OFD + GTR + DBBM
No SSD Better 
OFD + GTR + DBBM
No data
p = .03 p = .70 p = .05
MD = 1.05 MD = 0.18 MD = 0.77
95% CI: 0.09, 2.01 95% CI: −0.72, 1.08 95% CI: −0.01, 1.55
I2 = not applicable I2 = not applicable I2 = not aplicable
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
1 study
RoB: 1 unclear
Low strength of evidence
Abbreviations: OFD, open flap debridement; RP, all regenerative procedures; PPF, papilla preservation flap; PRF, platelet rich fibrin; DBBM, 
demineralized bovine bone mineral; SSD, statistically significant difference; GTR, guided tissue regeneration; GTR-RN, guided tissue regeneration 
non resorbable; GTR-R, guided tissue regeneration resorbable; DFDBA, demineralized freezed dried bone allograft; PRP, plateler rich plasma; HA, 
hydroxyapatite; AB, autogenous bone; bTCP, beta-tricalcium phosphate; HA/bTCP, hydroxyapatite/beta-tricalcium phosphate; BG, bioactive glass; 
HA, hydroxyapatite; RoB, number of studies at low, unclear or high risk of bias among the studies included in the meta-analysis.
TA B L E  3   (Continued)
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was observed comparing test and control group. These data clearly 
support the concept that application of EMD is an effective, tool for 
regeneration of intra-bony defects.
In recent years, the use of EMD has often been combined with 
bone filler materials, especially in large/not self-contained intra-bony 
defects, where a physical support is considered necessary. Overall, 
the addition of bone filler (AB, bTCP, HAbTCP, Bglass, DBBM) to 
EMD resulted in improved CAL gain (0.41 mm; 0.13–0.69; moderate 
strength of evidence), PPD reduction (0.40 mm; 0.15–0.64; moderate 
strength of evidence) and radiographic bone gain (0.67 mm; 0.40–
0.94 mm, moderate strength of evidence) compared with EMD alone. 
It should be taken in mind that in the present meta-analysis a group of 
heterogeneous bone filler was considered. Finally, only single study 
showing statistically significant improvements with the use of bone 
filler was published by Zucchelli and co-workers, who used DBBM as 
adjunct to EMD (Zucchelli, Amore, Montebugnoli, & Sanctis, 2003).
The use of GTR compared with OFD alone (Figure 4) showed 
that the use of membranes was associated with improved CAL 
gain (1.15 mm; 0.48–1.82; low strength of evidence) and PD re-
duction (1.24 mm; 0.41–2.07; low strength of evidence) at 12-
month follow-up compared with flap surgery alone, although both 
comparisons resulted in high heterogeneity. No differences were 
detected between GTR and OFD alone in gingival recession and 
radiographic bone gain (although this comparison only included 
two studies). Interestingly, the use of non-resorbable titani-
um-reinforced barriers was associated with high clinical perfor-
mance in two clinical studies (Silvestri, Ricci, Rasperini, Sartori, 
& Cattaneo, 2000; Zucchelli et al., 2002). The only two studies 
directly comparing resorbable and non-resorbable membranes in-
cluded in this review (Christgau, Schmalz, Wenzel, & Hiller, 1997; 
Zybutz et al., 2000) showed similar clinical and radiographic out-
comes. Non-resorbable membranes were rarely applied in recent 
RCTs, owing to the high number of complications reported and 
the need of second surgery. It should also be taken into account 
that the popularity of sole barriers for periodontal regeneration 
decreased in the last 15 years, while combinations of resorbable 
membranes and replacement biomaterials have become a fre-
quent treatment option. Specific cases where the operator may 
choose to use non-resorbable membranes based on defect mor-
phology still exist.
Favourable clinical and radiographic results were also detected 
with the addition of DBBM to GTR, with significantly higher CAL 
gain (1.5 mm; 0.66–2.34; low strength of evidence) and PD reduc-
tion (1.13 mm; 0.42–1.84; low strength of evidence) compared with 
flap access alone. This finding seems to suggest that this combina-
tion may be an effective treatment option especially in larger, not 
F I G U R E  3   Comparison between open flap for debridement plus enamel matrix derivatives (OFD vs. OFD + EMD) versus OFD alone in 
terms of final clinical attachment level gain (CAL gain)
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supporting defects where there is a risk of apical collapse of the 
barrier. Interestingly, two RCTs supported the long-term stability 
of GTR + DBBM (Sculean, Schwarz, et al., 2007; Stavropoulos & 
Karring, 2010), thus suggesting that the achieved outcomes in terms 
of CAL gain (2.09 mm; 1.33–2.86; moderate strength of evidence) 
were stable after at least 5 years of supportive periodontal therapy. 
This finding was also confirmed in a 10-year follow-up study com-
paring EMD + DBBM versus EMD + β TCP (Döri, Arweiler, Szántó, 
et al., 2013). Conversely, data from the present study recommend 
caution in applying multiple combinations when treating intra-bony 
defects, since some specific biomaterials as bioactive glass or HA/
bTCP did not improve the efficacy of EMD alone (De Leonardis & 
Paolantonio, 2013; Losada, Gonzalez, Garcia, Santos, & Nart, 2017; 
Meyle et al., 2011; Sculean, Pietruska, et al., 2005).
No statistically significant differences in clinical and radiographic 
outcomes were detected in the comparison between EMD and GTR 
for intra-bony defects. This is further confirmation of the similar 
magnitude of differences in PD, CAL and radiographic bone gain 
seen in the EMD versus open flap and GTR versus open flap analyses 
above. Equally, no clinical or radiographic differences were detected 
when EMD was compared with bone filler (with no membrane), al-
though this meta-analysis included only two studies and had high 
heterogeneity. Noteworthy, EMD is probably more user-friendly and 
generally associated with limited number of complications compared 
with barriers (Sanz et al., 2004).
Some of the studies included in both the EMD and GTR com-
parisons included the use of papilla preservation flaps. It is difficult 
to make clear conclusions about the differences between simple 
conventional flaps (sOFD) and papilla preservation flaps (PPF), al-
though the latter seem to be associated with increased CAL gain 
and reduced gingival recession, in line with what has been sug-
gested elsewhere (Cortellini & Tonetti, 2011; Schincaglia, Hebert, 
Farina, Simonelli, & Trombelli, 2015). In this context, it is important 
to highlight how studies have consistently shown no differences in 
clinical and radiographic outcomes when GTR (Trombelli, Simonelli, 
Pramstraller, Wikesjo, & Farina, 2010) or EMD (Cortellini & Tonetti, 
2011) was used as adjunct to minimally invasive surgeries, as ob-
served in a recent meta-analysis (Liu, Hu, Zhang, Li, & Song, 2016).
The use of PRP/PRF in addition to OFD for intra-bony defects 
seems to result in improved clinical and radiographic outcomes. 
However, the meta-analysis included only two studies published by 
the same research group (Agarwal & Gupta, 2014; Agarwal, Gupta, & 
Jain, 2016) and reported high levels of heterogeneity. In addition, no 
human histologic evidence of regeneration has been demonstrated 
and it should be also kept in mind that additional problems related 
to possible law restrictions in different countries may complicate the 
use of this product. Further research, however, is needed to reach a 
conclusion and clinical guidelines for their use.
Studies included in this review covered almost three decades, 
ranging in publication year from 1990 to 2019. Interestingly, there is 
F I G U R E  4   Comparison between open flap for debridement plus guided tissue regeneration (OFD vs. OFD + GTR) versus OFD alone in 
terms of final clinical attachment level gain (CAL gain)
     |  345NIBALI et AL.
a tendency in detecting higher clinical performance of regenerative 
procedures in the last decade compared with studies published in 
the ‘90s. This may be related to the growing popularity of papillary 
preservation flaps for regeneration, which reduced the incidence of 
early flap dehiscence over the wound area. Furthermore, this pos-
itive trend could be also related to the positive learning curve of 
the operators after early attempts in regeneration, along with the 
application of modern devices, including biologicals and resorbable 
barriers, which reduced post-operative morbidity and rate of regen-
eration failures. Furthermore, in the last 20 years important multi-
centre studies (Cortellini, Carnevale, Sanz, & Tonetti, 1998; Sanz 
et al., 2004; Tonetti, Cortellini, et al., 2004; Tonetti et al., 2002) 
confirmed the clinical efficacy of regeneration procedures but also 
highlighted a certain degree of variability of the clinical outcomes 
among different settings. This variability, named “centre-effect,” 
accounted for approximately 2 mm in clinical attachment gain and 
could be explained by possible factors including surgical ability of 
the operators, different expertise in clinical setting in terms of pa-
tient selection, efficacy of previous cause-related therapy and sup-
portive periodontal care programmes. From a clinical perspective, 
this SR confirmed the superiority of EMD and GTR in combination 
with papillary preservation flap for the treatment of infrabony 
defects compared with OFD (Pagliaro et al., 2008). Interestingly, 
among the selected biomaterials, only DBM seems to promote clin-
ical outcomes.
The “risk of bias assessment” in the single studies showed a ten-
dency to improve over time, since 8 out of 10 studies rated at low 
risk were published after 2011. Twenty-four studies did not report 
how to conceal the allocation and were considered at unclear risk 
even if the other six items were rated at low risk showing a good 
design. Fourteen studies were rated at high risk of bias. In a chrono-
logical perspective, it seems that introduction of CONSORT guide-
lines has improved study quality, leading to a decrease of items with 
unclear risk of bias.
When evaluating the strength of evidence through the modified 
GRADE assessment (Guyatt et al., 2008), only one out of twelve 
meta-analysis was rated at moderate strength of evidence, while the 
others were at low strength of evidence. These data seem to suggest 
caution in data interpretation and also reduce the generalizability of 
the results. Furthermore, this observation corroborates the need to 
minimize bias in future studies on periodontal regeneration.
Finally, as it became evident that some limitations of this inves-
tigation can be outlined, a thorough literature search for this review 
gave the authors the opportunity to notice a paucity of data about, 
“tooth loss,” “pocket closure” and “numbers needed to treat” to 
achieve successful clinical outcomes. This limits the clinical applica-
bility of the conclusions. Furthermore, data on adverse events are 
not consistently reported in the different studies and there is a lack 
of data about patient-reported outcomes and health economics of 
regenerative treatment of intra-bony defects. Only a limited num-
ber of studies reporting on long-term results after the regenerative 
approaches were identified through our search, and meta-analyses 
over 1 year of follow-up could not be performed, therefore limiting 
the generalizability of our conclusions. Finally, limited information 
was provided by the authors in relation to the defect configuration, 
for example the number of defect walls, the defect depth and the 
radiographic angulation. Interestingly, the use of systemic antibiotics 
was reported in 58 studies (Appendix S7), while in the others, it was 
not reported or unclear. Considering heterogeneity in terms of type 
of antibiotics and duration of treatment, it was not possible to per-
form further analysis or to provide specific recommendation.
It is also worth stressing that results observed in this SR refer 
to deep (≥3 mm radiographically) defects with residual pockets fol-
lowing non-surgical therapy. Modern approach for not-surgical root 
debridement may achieve optimal outcomes in terms of pocket re-
duction and elimination of bleeding on probing thus reducing the 
possible need for further surgery (Nibali, Yeh, Pometti, & Tu, 2018).
6  | CONCLUSIONS
According to data presented in this systematic review, it can be con-
cluded that there is low to moderate strength of evidence that:
• EMD and resorbable GTR appear to be the gold standard for the 
surgical treatment of deep (≥3 mm) intra-bony defects, which 
have not resolved following completion of non-surgical therapy.
• Among the possible replacement biomaterials, DBBM improved 
clinical outcomes of both EMD and resorbable GTR compared 
with OFD and it should be considered a viable treatment option 
especially in non-supporting defects.
• Non-resorbable GTR provides higher benefit compared with OFD; 
however, increased patient morbidity and incidence of post-oper-
ative complications, such as membrane exposure, are reported.
• Papillary preservation flaps improve the clinical outcomes and 
should be considered a surgical pre-requisite when performing 
any regeneration procedure.
• Limited evidence suggests that PRP/PRF may improve the clini-
cal parameters, but histologic evidence of regeneration has not 
clearly demonstrated.
7  | INDIC ATIONS FOR FUTURE RESE ARCH
• Increased number of studies assessing clinical efficacy and histo-
logic evidence of regeneration for PRP/PRF is suggested.
• Trials assessing the efficacy of different regenerative procedures 
for different defect morphologies are suggested, since different 
techniques may actually have different indications.
• RCTs assessing the long-term outcomes of periodontal regenera-
tion outcomes and including long-term data on PROMs, adverse 
events and health economics data are encouraged.
• The use of CONSORT guidelines to minimize the risk of bias is 
strongly encouraged.
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